HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $158 Price Target
10/15/2026
Impact: 75
Healthcare
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Dianthus Therapeutics (NASDAQ: DNTH) and maintained a price target of $158 for the stock.
AI summary, not financial advice
Share: